Literature DB >> 21153205

Synthesis and secretion of glucagon-like peptide-1 by fetal rat intestinal cells in culture.

T H Jackson Huang1, P L Brubaker.   

Abstract

Secretion of the intestinal proglucagon-derived peptides (PGDPs) including the incretin glucagon-like peptide-1 (GLP-1) is regulated, at least in part, by the duodenal hormone glucose-dependent insulinotropic peptide (GIP) through a protein kinase (PK) A-dependent pathway. It has been demonstrated that the activation of PKA increases the synthesis of some intestinal PGDPs, particularly the glucagon-like immunoreactive (GLI) peptides glicentin and oxyntomodulin. However, the effects of GIP on GLI and GLP-1 synthesis are not known. Fetal rat intestinal cells in culture were therefore treated for up to 24 h with 5MM: dbcAMP or 10(-6) M: GIP and the changes in glicentin, oxyntomodulin, GLP-1(x-37) and GLP-1(x-36NH2) secretion and synthesis were examined by RIA and HPLC. Both dbcAMP and GIP increased the acute (2 h; to 224±21 and 256±20% of controls, respectively,P<0.001) and chronic (24 h; to 230±22 and 130±6% of controls, respectively,P<0.001) secretion of intestinal PGDPs. In contrast, the total culture content of PGDPs was increased only after 24 h of incubation (to 156±15 and 125±7% of controls for dbcAMP and GIP, respectively,P<0.01). HPLC analysis confirmed that the intestinal cultures produced the GLI peptides glicentin and oxyntomodulin, as well as the biologically active forms of GLP-1, GLP-7(7-37) and GLP-1(7-36NH2). The relative proportion of these peptides was not altered by treatment with dbcAMP or GIP. Thus, in addition to its effects on GLP-1 release from the rat intestine, GIP appears to be an important regulator of the synthesis of this insulinotropic peptide.

Entities:  

Year:  1995        PMID: 21153205     DOI: 10.1007/BF02738824

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  36 in total

1.  Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas.

Authors:  S Mojsov; M G Kopczynski; J F Habener
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

2.  Alpha-cell-specific expression of the glucagon gene is conferred to the glucagon promoter element by the interactions of DNA-binding proteins.

Authors:  J Philippe; D J Drucker; W Knepel; L Jepeal; Z Misulovin; J F Habener
Journal:  Mol Cell Biol       Date:  1988-11       Impact factor: 4.272

3.  The characterization of the ascorbic acid-mediated alpha-amidation of alpha-melanotropin in cultured intermediate pituitary lobe cells.

Authors:  C C Glembotski
Journal:  Endocrinology       Date:  1986-04       Impact factor: 4.736

4.  Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides.

Authors:  P L Brubaker
Journal:  Endocrinology       Date:  1991-06       Impact factor: 4.736

5.  Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.

Authors:  D M Nathan; E Schreiber; H Fogel; S Mojsov; J F Habener
Journal:  Diabetes Care       Date:  1992-02       Impact factor: 19.112

6.  Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.

Authors:  C Orskov; J J Holst; S Knuhtsen; F G Baldissera; S S Poulsen; O V Nielsen
Journal:  Endocrinology       Date:  1986-10       Impact factor: 4.736

7.  Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes.

Authors:  P L Brubaker; D C So; D J Drucker
Journal:  Endocrinology       Date:  1989-06       Impact factor: 4.736

8.  Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat.

Authors:  A Kervran; P Blache; D Bataille
Journal:  Endocrinology       Date:  1987-08       Impact factor: 4.736

9.  Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

Authors:  R M Elliott; L M Morgan; J A Tredger; S Deacon; J Wright; V Marks
Journal:  J Endocrinol       Date:  1993-07       Impact factor: 4.286

10.  The multifunctional peptidylglycine alpha-amidating monooxygenase gene: exon/intron organization of catalytic, processing, and routing domains.

Authors:  L H Ouafik; D A Stoffers; T A Campbell; R C Johnson; B T Bloomquist; R E Mains; B A Eipper
Journal:  Mol Endocrinol       Date:  1992-10
View more
  5 in total

1.  Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release.

Authors:  P L Brubaker; S Efendic; G R Greenberg
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

Review 2.  Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors:  Lin Li
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

3.  Inverse association between maternal 25OHD level and cord GLP-1/GIP concentrations.

Authors:  Shimpei Niwa; Hidetoshi Mezawa; Naoaki Kobayashi; Hiroyuki Ida; Mitsuyoshi Urashima
Journal:  Pediatr Res       Date:  2015-12-09       Impact factor: 3.756

4.  Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy.

Authors:  Li Lin
Journal:  Clin Med Pathol       Date:  2008-07-28

5.  Effects of passage through the digestive tract on incretin secretion: Before and after birth.

Authors:  Seiichi Tomotaki; Ryosuke Araki; Kouji Motokura; Yutaro Tomobe; Takeru Yamauchi; Shintaro Hanaoka; Hiroko Tomotaki; Kougoro Iwanaga; Fusako Niwa; Junko Takita; Masahiko Kawai
Journal:  J Diabetes Investig       Date:  2020-11-28       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.